Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.
Alicia J Jenkins; Rachel L O'Connell; Andrzej S Januszewski; Angela C Webster; Timothy M E Davis; Meg J Jardine; Russell S Scott; Marja-Riitta Taskinen; Anthony C Keech;
Abstract
Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.
| Journal | DIABETES RESEARCH AND CLINICAL PRACTICE |
| ISSN | 1872-8227 |
| Published | 01 Apr 2024 |
| Volume | 210 |
| Issue | |
| Pages | 111612 |
| DOI | 10.1016/j.diabres.2024.111612 |
| Type | Journal Article |
| Sponsorship | NHMRC: 2024025 |
